メニュー
Recommends careful DDAVP and fluid intake titration including frequent weighing and serum sodium level monitoring for adipsic diabetes insipidus. Use when managing adipsic DI requiring fluid balance management.
デフォルトでは、最初にソースを確認する Prompt が選択されています。直接コマンドに切り替えるか、ローカルコピーをダウンロードすることもできます。
インストールを決める前に、SKILL.md と SkillsMP に表示されている付属ファイルをお読みください。
SOC 職業分類に基づく
Codex または Claude でインストール この Prompt をコピーして Codex、Claude、または他のアシスタントに貼り付けると、Skill ページを確認してインストールできます。
直接コマンドでは確認用 Prompt が省略されます。実行前にソースを確認してください。
npx skills add https://github.com/dromlakhani/MD2SKILL --skill ata-adipsic-di-titrationコマンドは1行のまま表示されます。コピー前に横へスクロールして全体を確認してください。
ローカルで確認しますか？SkillsMP が現在取得できるファイルをダウンロードできます。
SKILL.md を表示中
For a person with confirmed islet autoantibodies (early-stage type 1 diabetes), state the numerical progression risk to Stage 3 T1D by stage and age, set the age-stratified monitoring frequency (metabolic and HbA1c), apply the ≥10% longitudinal HbA1c rise → OGTT rule, and give the standard risk-modifier and communication framing. Use when a clinician asks how often should I monitor this Stage 1 child, what's the risk of this teenager progressing to insulin, adult with GAD positive what's the 5-year risk, my patient's HbA1c has risen 12% is that important, single autoantibody how often to retest, or how to counsel a family about progression risk. Grounded in Phillip et al. Diabetologia 2024 international staging and monitoring consensus, cross-referenced with Hussain et al 2026 IDF Europe roadmap.
Order and confirm islet autoantibody screening for early-stage type 1 diabetes — which antibodies to test (GAD65, IAA, IA2, ZnT8), sample types (capillary dried blood spot, venous), the mandatory two-sample two-method confirmation protocol, and how to interpret a positive, negative, or single-antibody result. Use when a clinician asks how to screen for early T1D, which islet autoantibodies to order, how to confirm a positive T1D antibody screen, is one autoantibody enough for T1D diagnosis, GAD antibody positive what next, or is running a general population or family-history T1D screening program. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
Classify a person with a positive islet autoantibody screen into a specific stage of type 1 diabetes (At Risk / Stage 1 / Stage 2a / Stage 2b / Stage 3a / Stage 3b / Stage 4) using the international consensus staging framework based on autoantibody count and glycaemic status. Use when a clinician asks how to stage a positive autoantibody screen, what stage of T1D is this, is this early-stage T1D, does this child need insulin yet, is this presymptomatic T1D, does this qualify for teplizumab, or presents a person with any combination of islet autoantibodies + glucose data. Applies across paediatric and adult populations. Grounded in Hussain et al 2026 (Diabetes, Obesity and Metabolism, IDF Europe consensus, DOI 10.1111/dom.70569).
| name | ata-adipsic-di-titration |
| description | Recommends careful DDAVP and fluid intake titration including frequent weighing and serum sodium level monitoring for adipsic diabetes insipidus. Use when managing adipsic DI requiring fluid balance management. |
Collect baseline weight, daily fluid intake, serum sodium, urine output, and assess thirst mechanism.
→ Proceed to Step 2 once data are obtained.
Confirm adipsic DI (lack of thirst response) and rule out other causes of hyponatremia (e.g., SIADH, glucocorticoid excess).
→ If adipsic DI confirmed, proceed to Step 3; otherwise, reconsider diagnosis.
Classify serum sodium trend: stable (135‑145 mmol/L), mild hyponatremia (130‑134), moderate/severe (<130), or hypernatremia (>145).
→ Proceed to Step 4 based on classification.
For mild hyponatremia or weight gain: reduce DDAVP dose by 25‑50% and/or restrict fluid intake; for hypernatremia or weight loss: increase DDAVP dose or fluid intake; aim for stable weight and serum sodium 135‑145 mmol/L; reassess daily.
→ Continue monitoring and adjust as needed.
Avoid fixed DDAVP dosing without daily weight and sodium checks; do not impose fluid restriction without sodium monitoring; ensure a weekly off‑DDAVP period to allow polyuria; watch for over‑replacement causing hyponatremia and under‑replacement causing hypernatremia; educate patients on signs of fluid imbalance.
A 45‑year‑old post‑pituitary surgery patient with adipsic DI on DDAVP 10 µg BID reports stable weight and serum Na 138 mmol/L; after 3 days of weight gain 2 kg and Na dropping to 132 mmol/L, DDAVP is reduced to 5 µg BID and fluid intake limited to 1500 mL/day; daily weight and Na improve to ‑1 kg and 135 mmol/L, then dose is maintained.
Source: Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2016, DOI:10.1210/jc.2016-2118
TODO: consider adding scripts/calc.py for the ata-adipsic-di-titration calculator